MUCOBOOST - Randomized, controlled, multicenter Phase I/IIa study comparing the safety and immunogenicity of a booster dose of an intranasal COVID-19 vaccine expressing SARSCoV-2 N/S recombinant proteins with a booster dose of COVID-19 mRNA vaccine in healthy adults.
- Funded by Agence nationale de recherche sur le sida et les hépatites virale [National Agency for AIDS Research] (ANRS)
- Total publications:0 publications
Grant number: ANRS0514s
Grant search
Key facts
Disease
COVID-19Start & end year
2023Known Financial Commitments (USD)
$2,372,590.17Funder
Agence nationale de recherche sur le sida et les hépatites virale [National Agency for AIDS Research] (ANRS)Principal Investigator
DIMIER-POISSON IsabelleResearch Location
FranceLead Research Institution
Université de Tours (UMR ISP 1282)Research Priority Alignment
N/A
Research Category
Vaccines research, development and implementationResearch Subcategory
Phase 1 clinical trialSpecial Interest Tags
N/AStudy Type
ClinicalClinical Trial Details
Clinical Trial, Phase IBroad Policy Alignment
PendingAge Group
Adults (18 and older)Vulnerable Population
UnspecifiedOccupations of Interest
Unspecified
Abstract
N/A